ClinicalTrials.gg
RecruitingNCT06702826Updated Nov 25, 2024

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

A Phase 2 interventional study of Cadonilimab combined with SRS in Non Small Cell Lung Cancer, Brain Metastases and Stereotactic Radiation, sponsored by Rongrong Zhou. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Rongrong Zhou · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 13 under way, 2 of them phase 3. cadonilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
14th of 15
20 · median 44
Started
2024
with 2 others
Phase 2
11 of 15
8 open now
Primary completion
2027-11
later than 11 of 12 live
Registered
14th of 15
by date
Lead sponsor
1 of 15
Rongrong Zhou

Among the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).

The main questions it aims to answer are:

  • Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results?
  • Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC:
  • Receive Cadonilimab combined with SRT for brain lesions.
  • Visit the hospital regularly once every 12 weeks for checkups and tests
Read the detailed description

Lung cancer is the cancer with the highest morbidity and mortality in the world. The most common metastatic site of lung cancer is the brain.

Radiotherapy is a classic treatment for brain metastases from lung cancer. Stereotactic radiosurgery (SRS) has image-guided technology, which can accurately find the location of the tumor with an accuracy of millimeters, and effectively reduce the radiation to the surrounding normal tissues. According to the relevant recommendations of the NCCN guidelines for Central nervous System Tumors (first edition 2022), SRS can be given priority to patients with newly diagnosed localized brain metastases or with stable systemic tumor control, which can better protect the cognitive function of patients. SRS should be considered initial therapy in patients with a limited number of brain metastases. Citation (S) : SRS should be considered especially in patients with good physical activity status (PS) and small total tumor volume.

The brain was once considered to be an immune privilege organ, which can actively inhibit any immune response. The 2019 NCCN guidelines have recommended immune checkpoint inhibitors (ICIs) as the first-line treatment for some patients with lung cancer, and the application of ICIs in lung cancer with brain metastases is also being explored. Several phase III RCT studies have shown that immunotherapy prolongs the survival of patients with brain metastases.

As a classic treatment for brain metastases from lung cancer, radiotherapy can promote the anti-tumor immune effect by inducing immunogenic cell death, exposing tumor-associated antigens, activating dendritic cells, changing the tumor microenvironment, and enhancing the expression of intercellular adhesion molecule-1 (ICAM-1), Fas and major histocompatibility complex Ⅰ (MHCⅠ) in tumor cells. High-dose fractionated radiotherapy also has immunogenicity, which may open the blood-brain barrier (BBB) and promote the entry of ICI into brain tissue. However, radiotherapy can up-regulate the expression of PD-L1 and inhibit tumor immunity, which can be improved by ICI. In conclusion, intracranial radiotherapy combined with ICIs has feasibility and theoretical basis for the treatment of malignant tumors.

Cadonilimab is a bispecific antibody (BsAb) that can bind to both PD-1 and CTLA-4 with high affinity. It is a novel tumor immunotherapy drug with a quadrivalent structure and a short half-life, and has been shown to have less toxicity than the combination of anti-PD-1 and anti-CTLA-4 antibodies in monkey toxicity studies. These features make it possible that the use of Cadonilimab in cancer subjects may have better efficacy and safety.

In conclusion, the combination of Cadonilimab with radiotherapy has potential advantages and is expected to have the potential to further improve antitumor efficacy. Therefore, the aim of this study is to evaluate the efficacy and safety of Cadonilimab combined with SRS in the treatment of brain metastases from NSCLC, and to provide evidence for future studies.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Brain Metastases
  • Stereotactic Radiation
  • Immunotherapy

Keywords

  • non small cell lung cancer
  • brain metastases
  • SRS
  • immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ 75 years old; Both male and female;
  2. 0-1;
  3. or cytologically confirmed non-small cell lung cancer;
  4. Progression with after previous anti-tumor therapy;
  5. Requirements for brain metastases: ① measurable brain metastases without radiotherapy; ②SRS/FSRT: the maximum tumor volume of brain metastases was less than 10cm3, the single diameter was less than 3cm, and the total volume of brain metastases involved was less than 15 cm3.
  6. Response to previous therapy on the initial response assessment;
  7. If a lesion of the head has been irradiated, the cumulative radiation dose does not exceed the tolerated dose to all structures.
  8. For patients with measurable CNS lesions, the longest diameter on MRI images is ≥10mm, which is suitable for repeated and accurate measurement.
  9. Subjects were evaluated for all extracranial disease sites (e.g., by computed tomography (CT) scan and bone scan or positron emission tomography (PET-CT) within 14 days before the first dose.
  10. Subjects had to have a baseline brain MRI scan within 14 days before the first dose of medication.
  11. Estimated survival time > 12 weeks.
  12. Participants of childbearing age must agree to use effective during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
  13. Patients who are not lactating.
  14. Have definite and good organ functions:
  15. Provide voluntarily, and be willing and able to comply with the follow-up, treatment, laboratory testing, and other study requirements specified in the study schedule.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to participate in the study:

  1. Experienced grade 3-4 intracranial toxicity (pituitary or central nervous system toxicity);
  2. No measurable intracranial lesions without radiotherapy;
  3. Meningeal metastasis;
  4. If receiving chemotherapy or targeted therapy, the should not exceed 3 weeks; if receiving resection, the washout period should not exceed 2 weeks;
  5. Have significant diseases
  6. Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 () inhibitor.
  7. Previous (within 5 years) or concurrent other malignant tumors
  8. History of anaphylaxis to any monoclonal antibody and/or study drug component.
  9. A history of or current noninfectious pneumonia/interstitial lung disease requiring systemic .
  10. Serious infection within 4 weeks before the first dose.
  11. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  12. Subjects required systemic treatment with corticosteroids (>10mg prednisone equivalent per day) or other drugs within 14 days before taking the study drug.
  13. Patients with cardiovascular disease
  14. Enroll in another clinical study at the same time, unless it is an observational, noninterventional clinical study or a follow-up of an interventional study.
  15. Received within 30 days before the first dose, or planned to receive live vaccine during the study.
  16. Known history of mental illness, substance abuse, alcohol or drug abuse.
  17. Pregnant or lactating women.
  18. The presence of any past or current medical conditions, treatments, or laboratory abnormalities may confound the results of the study, interfere with the full participation of the subject in the study, or may not be in the best interest of the subject to participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cadonilimab combined with SRS

    Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone

    Drug: Cadonilimab combined with SRS

Interventions

  • DrugCadonilimab combined with SRS

    Drug page: CadonilimabStudies of CadonilimabCadonilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone

06

What researchers measure

Primary outcomes

  1. iORR

    Intracranial objective response rate (iORR) was defined as the proportion of patients who achieved a prespecified reduction in tumor volume and maintained the minimum time requirement, including CR and PR cases.

    Time frame: From date of enrollment until the date of first documented intracranial progression, assessed up to 2 years.

Secondary outcomes

  1. PFS

    Progression-free survival (PFS) : defined as the time from first use of a study drug to documentation of disease progression (according to RECIST v1.1) or death from any cause, whichever occurred first.

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

  2. iPFS

    Intracranial Progress Free Survival rate (iPFS) : the time from clinical detection of brain metastases to the first occurrence of intracranial progression or death. iPFS was assessed according to the Response Assessment of Brain Metastases in Neurooncology (RANO-BM) criteria.

    Time frame: From date of enrollment until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 2 years

  3. OS

    Overall survival (OS) : defined as time from treatment initiation to death from any cause.

    Time frame: From date of enrollment until the date of death from any cause, whichever came first, assessed up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 36 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 25, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06702826
Lead sponsor
Rongrong Zhou
Responsible party
Rongrong Zhou (Deputy Director of Department of Oncology, Xiangya Hospital of Central South University) — Sponsor-investigator
First posted
Nov 25, 2024
Start date
Nov 1, 2024
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 25, 2024

Study contacts

Rongrong Zhou, MD, PHD
Contact
zhourr@csu.edu.cn
+8613875898127

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion